Main menu

Press Release Archive

Press Release Archive

December 17, 2012 - Pfizer Invites Public To View And Listen To Webcast Of January 29 Conference Call With Analysts

(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EST on Tuesday, January 29, 2013. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Fourth Quarter 2012 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.

December 17, 2012 - Pfizer Declares First-Quarter 2013 Dividend

(BUSINESS WIRE)--The board of directors of Pfizer Inc. (NYSE: PFE) today declared a 24-cent first-quarter 2013 dividend on the company’s common stock, payable March 5, 2013, to shareholders of record at the close of business on February 1, 2013. Pfizer increased the dividend by approximately 9 percent, to 24 cents from 22 cents per share. The first-quarter 2013 cash dividend will be the 297th consecutive quarterly dividend paid by Pfizer

December 13, 2012 - U.S. Food And Drug Administration (FDA) Accepts New Drug Application For Bazedoxifene/Conjugated Estrogens, An Investigational Treatment For Symptoms Associated With Menopause And Prevention Of Osteoporosis

(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that the United States Food and Drug Administration (FDA) accepted for review a New Drug Application (NDA) for bazedoxifene/conjugated estrogens (BZA/CE), a potential new medicine for non-hysterectomized women for the treatment of moderate-to-severe vasomotor symptoms (VMS) and vulvar and vaginal atrophy (VVA) associated with menopause, as well as the

December 11, 2012 - New Robitussin® COUGHCAST™ Tool Helps Consumers Prepare for Coughs, Colds and the Flu by Tracking Cough Incidence Rates in Their Area

(BUSINESS WIRE)--‘Tis the season for shopping, parties, luncheons and hustle and bustle. This year, Robitussin® wants to help make sure you don’t have to take an unnecessary and unwanted “time-out” from holiday festivities due to a cough, cold or the flu. Already this year, the U.S. has experienced its earliest flu season in nearly 10 years and areas across the country are seeing higher-than-normal flu rates, according to the Centers for Disease Control

December 8, 2012 - ELIQUIS® (apixaban) Demonstrated Superiority In Reducing A Composite Of Recurrent Venous Thromboembolism And All-Cause Death Without Increasing The Rate Of Major Bleeding Versus Placebo During One Year Of Extended Treatment

Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) today announced the results of the Phase 3 AMPLIFY-EXT trial, which evaluated treatment with ELIQUIS® (apixaban) over a one-year period compared to placebo for the prevention of recurrent venous thromboembolism (VTE) in 2,486 patients who had already completed 6 to 12 months of anticoagulation treatment for VTE, including deep vein thrombosis (DVT) or pulmonary embolism

December 4, 2012 - Tanzania Expands Immunization Program To Include Pfizer’s Prevenar 13 For Prevention Of Pneumococcal Disease

Pfizer Inc. (NYSE: PFE) welcomes today’s announcement from the GAVI Alliance that Pfizer’s pneumococcal conjugate vaccine, Prevenar 13* (pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]), is now included in the expanded pediatric immunization program in Tanzania. Pneumococcal disease is one of the leading causes of vaccine-preventable deaths worldwide in children younger than 5 years of age and results in more than one out of

December 4, 2012 - Pfizer Presents Phase 2 Data Showing Investigational Therapy PD-0332991 Plus Letrozole Significantly Improved Progression Free Survival Compared With Letrozole Alone In Patients With ER Positive, HER2 Negative Advanced Breast Cancer

(BUSINESS WIRE)--Pfizer Inc. today announced randomized Phase 2 data that showed PD-0332991 (PD-991) in combination with letrozole significantly extended progression free survival (PFS) compared with letrozole alone in post-menopausal patients with estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) locally advanced or metastatic breast cancer. For patients treated with the combination of PD-991 plus letrozole, median PFS

November 30, 2012 - Pfizer Completes Sale of Nutrition Business to Nestlé

(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that it has completed the sale of its Nutrition business to Nestlé for $11.85 billion in cash, following the conclusion of the required regulatory process in most markets. In certain countries where completion will be delayed due to ongoing regulatory review, Pfizer will continue to operate the business on an interim basis. “The completion of the sale of the Nutrition business to Nestlé

November 28, 2012 - Pfizer to Present Clinical Data from Its Hematology Portfolio at the 54th Annual Meeting of the American Society of Hematology

(BUSINESS WIRE)--Pfizer Oncology will present updated data in chronic myeloid leukemia (CML) for its oral Abl and Src kinase inhibitor, BOSULIF®(bosutinib),12,3,4,5recently approved by the U.S. Food and Drug Administration (FDA), and new data in acute lymphoblastic leukemia (ALL) and non-Hodgkin’s lymphoma (NHL) for inotuzumab ozogamicin,6,7a CD-22 directed antibody drug conjugate (ADC) that is currently being studied in two Phase 3 trials (INO-VATE trials),8,

November 27, 2012 - Pfizer Acquires NextWave Pharmaceuticals, Inc.

(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that it has completed its acquisition of NextWave Pharmaceuticals, Inc., a privately held, specialty pharmaceutical company focused on the development and commercialization of products for the treatment of attention deficit hyperactivity disorder (ADHD). Upon the closing of the transaction, Pfizer now holds exclusive North American commercialization rights to Quillivant XR™ (methylphenidate

November 25, 2012 - Pfizer Subsidiary, Wyeth LLC, to Redeem 5.500% Notes Due March 15, 2013

Pfizer Inc. (NYSE: PFE) today announced that Wyeth LLC, its wholly-owned subsidiary, has notified The Bank of New York Mellon, as trustee under the applicable indenture, of its election to fully redeem all of its outstanding 5.500% Notes due March 15, 2013 (after giving effect to a December 4, 2003 upward interest rate adjustment of 0.25%) (CUSIP No. 983024AA8) (the “Notes”). The aggregate principal amount of Notes currently outstanding is $1.5

November 20, 2012 - ELIQUIS®(apixaban) Approved in Europe for Prevention of Stroke and Systemic Embolism in Patients with Nonvalvular Atrial Fibrillation

(BUSINESS WIRE)--Bristol-Myers Squibb (NYSE: BMY) and Pfizer (NYSE: PFE) announced today that the European Commission has approved ELIQUIS® (apixaban) for prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation (NVAF) with one or more risk factors. ELIQUIS is the only oral anticoagulant that has demonstrated superior risk reduction versus warfarin in the three important outcomes of stroke and systemic embolism, major

November 19, 2012 - Cystic Fibrosis Foundation Therapeutics Announces $58 Million CF Drug Discovery Agreement with Pfizer

Cystic Fibrosis Foundation Therapeutics Inc. (CFFT), the nonprofit drug discovery and development affiliate of the Cystic Fibrosis Foundation, today announced a major expansion of its research collaboration with Pfizer Inc. designed to discover new drugs to treat people with the most common mutation of CF, Delta F508. Under the new six-year pre-clinical research program with Pfizer, CFFT will invest up to $58 million to speed the discovery and development of potential therapies that target themore...

November 18, 2012 - Pfizer Reports Top-Line Results Of A Phase 3 Study Evaluating Pregabalin Controlled-Release As Treatment For Patients With Fibromyalgia

(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that top-line results of a double-blind, Phase 3 study evaluating pregabalin controlled-release (CR) formulation in patients with fibromyalgia indicate that pregabalin CR had a statistically significant positive effect compared to placebo in the primary endpoint, time to loss of therapeutic response (LTR). Fibromyalgia is a common pain condition in the United States, affecting more than five million

November 15, 2012 - Pfizer Reports Top-Line Results Of A Phase 3 Study Evaluating Pregabalin Controlled-Release Formulation As Adjunctive Treatment In Adult Patients With Partial Onset Seizures

(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced top-line results of a double-blind, placebo-controlled, Phase 3 study evaluating both the 165 mg dose and the 330 mg dose of pregabalin controlled-release (CR) formulation in adult patients with partial onset seizures with epilepsy. These study results indicate pregabalin CR did not meet its primary endpoint comparing the change in seizure frequency to placebo, although both doses were well-toleratedmore...

November 12, 2012 - Best-Selling Author and Award-Winning Life Coach, Gail Blanke, Leads the Charge for Disease Awareness During National Chronic Obstructive Pulmonary Disease (COPD) Awareness Month

Boehringer Ingelheim Pharmaceuticals, Inc. and Pfizer Inc (NYSE: PFE), in partnership with best-selling author and award-winning life coach, Gail Blanke, announced today the launch ofBetter Breathing is Possible, an educational campaign designed to teach people with chronic obstructive pulmonary disease, or COPD, steps to help manage their COPD and why it is beneficial. The campaign launch coincides with the World COPD Day observance, which will raise awareness among the COPD community

November 12, 2012 - Amgen and Pfizer Highlight Data to be Presented at American College of Rheumatology Meeting

Amgen (NASDAQ:AMGN) andPfizer (NYSE:PFE) today announced that results from several Enbrel® (etanercept) studies will be presented at the American College of Rheumatology/Association of Rheumatology Health Professionals(ACR/ARHP) 2012 Annual Meeting in Washington, D.C. from Nov. 10-14, 2012."Moderate to severe rheumatoid arthritis (RA) places a significant burden on patients, and we are pleased that ENBREL remains the number one most prescribed biologic among

November 7, 2012 - MULTIMEDIA: U.S. Food And Drug Administration Approves Pfizer’s XELJANZ® (tofacitinib citrate) for Adults with Moderately to Severely Active Rheumatoid Arthritis (RA) Who Have Had an Inadequate Response or Intolerance to Methotrexate

(BUSINESS WIRE)--This release has been updated with multimedia. Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved XELJANZ® (tofacitinib citrate) 5 mg twice daily for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to methotrexate. XELJANZ may be used as monotherapy or in combination with methotrexate or other non-

November 6, 2012 - Auxilium and Pfizer Will Conclude Agreement on XIAPEX® EU Collaboration

Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, and Pfizer Inc. (NYSE: PFE) are amending their collaboration agreement for the development, commercialization and supply of XIAPEX in the European Union (EU) and certain other European and Eurasian countries (the “Collaboration Agreement”). As a result of this amendment, the Collaboration Agreement will terminate no later than April 24, 2013. Prior to the mutual termination date, the parties will continue to

November 6, 2012 - U.S. Food and Drug Administration Approval of XELJANZ® (tofacitinib citrate) and Invitation to Media Briefing from Pfizer

U.S. Food and Drug Administration Approval of XELJANZ® (tofacitinib citrate) and Invitation to Media Briefing from Pfizer 11/6/12 5:25 pm ESTNEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) has received approval from the U.S. Food and Drug Administration (FDA) for XELJANZ® (tofacitinib citrate) 5 mg twice daily for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to methotrexate. XELJANZ may be used as monotherapy or in combination with methotrexate or other non-biologic disease-modifying antirheumatic drugs (DMARDs).


Note: These press releases were issued in the United States and are intended as reference information for U.S. investors and journalists. The information contained in each press release was accurate at the time of issuance, and Pfizer assumes no responsibility for updating the information to reflect subsequent developments.


Stock Quote Disclaimer

20 minute delayed data provided by Comstock. Charts are provided by BigCharts and MarketWatch, Inc. Pfizer makes no claims concerning the accuracy of the information provided on these pages, and will not be held liable for any use of this information. Note: Historical and current stock price performance data is not necessarily indicative of future performance.


If you do not have Adobe® Reader, download it here. It is available without charge from Adobe®. This link is provided as a convenience. Pfizer is not responsible for the content of this linked page.

Current Stock Price

. .
%Change . 52 Wk. High .
Day High . 52 Wk. Low .
Day Low . Mkt. Cap(Mil) .
Open .    
Prev Close . Symbol .
Vol. . Exchange .

Online Pfizer Press Kit

Our press kit provides information that might help you write stories or simply find out more about Pfizer.